Arrowhead Pharmaceuticals Announces New Phase 2 Data of …
https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-new-phase-2-data-plozasiran
WEBApr 7, 2024 · Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG). Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions …
DA: 63 PA: 29 MOZ Rank: 41